Rice Technologies for Cervical Cancer Screening and Diagnosis

Recruiting now · Not applicable

Conditions studied: Cervical Cancer

In brief

The study aims to compare the accuracy of the lateral flow test to detect HPV at the POC with commercially available HPV test and to determine the diagnostic accuracy and reliability of a multimodal optical imaging system to detect cervical dysplasia, with the gold reference standard of histopathology.

Key facts

Study ID

NCT05372484

Run by

M.D. Anderson Cancer Center

People needed

678

Starts

2021-03-24

Expected to finish

2028-03-30

Last updated by the study team

2026-02-13

Who can join

Age: 25 and older, up to 49. Sex: female. Healthy volunteers: not accepted.

You may qualify if…

• 25 - 49 year old women
• Women with a positive cervical cancer screening test (abnormal cytology, positive VIA and/or positive HPV test)
• Women with intact cervix
• Women who are not pregnant and with a negative pregnancy test (within 14 days from the date of enrollment) ) and not currently breastfeeding
• Willing and capable of providing informed consent

You may not qualify if…

• Women under 25 or over 49 years old
• Women who have undergone a total hysterectomy (with removal of the cervix)
• Women who are pregnant or breastfeeding

Where it is running

• M D Anderson Cancer Center — Houston, Texas, United States (enrolling)
• José Macamo General Hospital and Health Center — Maputo, Mozambique (enrolling)
• Maputo Central Hospital — Maputo, Mozambique (enrolling)
• Mavalane Hospital and Health Center — Maputo, Mozambique (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.